Aprea Therapeutics (APRE) Shares Outstanding (2018 - 2026)

Aprea Therapeutics (APRE) has reported Shares Outstanding (Entity) for 9 consecutive years, with $12.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Shares Outstanding (Entity) rose 117.37% year-over-year to $12.0 million; the TTM figure through Mar 2026 stood at $12.0 million (up 117.37% YoY), while the FY2025 annual figure was $6.5 million, up 19.3% from the prior year.
• Shares Outstanding (Entity) improved to $12.0 million in Q1 2026 per APRE's latest filing, from $6.5 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $12.0 million in Q1 2026 and bottomed at $1.1 million in Q1 2022.
• Historically, Shares Outstanding (Entity) has averaged $4.5 million across 5 years, with a median of $4.2 million in 2024.
• Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) increased 3.72% — and 2023, when it surged 239.63%.
• Aprea Therapeutics' Shares Outstanding (Entity) stood at $1.7 million in 2022, then surged by 125.5% to $3.7 million in 2023, then soared by 46.68% to $5.5 million in 2024, then climbed by 19.3% to $6.5 million in 2025, then soared by 83.26% to $12.0 million in 2026.
• Business Quant data shows APRE's Shares Outstanding (Entity) at $12.0 million in Q1 2026, $6.5 million in Q4 2025, and $6.0 million in Q3 2025.